Equip ISGlobal - Títol

Equip ISGlobal


Elisa Sicuri holds a Ph.D. in Economics from the University of Pavia (Italy). In addition to her (0.5FTE) position as Associate Research Professor at ISGlobal and as Associate Professor at the University of Barcelona (UB), she currently holds a part-time research position at the Department of Health Policy, London School of Economics and Political Science. From 2015 to 2020 she was a Research Fellow at the Department of Infectious disease epidemiology, Imperial College London

Elisa Sicuri works on health economics in low- and middle-income countries. Her research focuses on the economics of infectious diseases, particularly of neglected tropical diseases/vector-borne diseases, and includes a range of studies: cost-effectiveness/cost-benefit analysis of health interventions, analysis of the market for health products, and impact evaluation of infectious diseases (interventions) on economic indicators.

She is currently leading the economic workstream of a number of large projects, including “Vaccine for prevention and treatment of Trypanosoma cruzi infection (CRUZIVAX)”, “Fast and reliable easy-to-use diagnostics for eliminating Bilharzia in young children and mothers (FreeBILy)” and “Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic (ORCHESTRA)” among others.

She is also contributing to the health economics workstreams of the studies “Prevention and management tools for reducing antibiotic resistance in high prevalence settings (REVERSE)”, “Indo-European Consortium for Next Generation Influenza Vaccine Innovation (INCENTIVE)” projects, and “Phase 3 evaluation of an innovative simple molecular test for the diagnosis of malaria in different endemic and health settings in Sub-Saharan Africa (DIAGMAL)”.

She leads a team of health economists. Current and past team members are: Scherif Adegnika, Celine Aerts, Sergi Alonso, Joe Brew, Laia Cirera, Iris Lopes, and Francesco Ramponi

Línies de recerca

Her research focuses on the economics of vector-borne diseases and includes a range of studies:
  • Impact evaluation and cost-effectiveness/cost-benefit analysis of health interventions. 
  • Analysis of the market for health products.
  • Analysis of the relationship between health and development.

Publicacions principals

  • Aerts C, Vink M, Pashtoon SJ, Nahzat S, Picado A, Cruz I, Sicuri E. Cost Effectiveness of New Diagnostic Tools for Cutaneous Leishmaniasis in Afghanistan. Appl Health Econ Health Policy. 2019 Apr;17(2):213-230. doi:10.1007/s40258-018-0449-8.
  • Aerts C, Sunyoto T, Tediosi F, Sicuri E. Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature. Health Policy. 2017 Jul;121(7):745-754. doi:10.1016/j.healthpol.2017.05.005.
  • Alonso S, Munguambe K, Sicuri E. Market for Artemether-Lumefantrine to treat childhood malaria in a district of southern Mozambique. Health Econ. 2017 Dec;26(12):e345-e360. doi: 10.1002/hec.3514.
  • Requena-Méndez A, Bussion S, Aldasoro E, Jackson Y, Angheben A, Moore D, Pinazo MJ, Gascón J, Muñoz J, Sicuri E. Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis. Lancet Glob Health. 2017 Apr;5(4):e439-e447. doi: 10.1016/S2214-109X(17)30073-6. Epub 2017 Feb 28. PMID: 28256340.
Publicador de continguts